← All Evogene LTD filings

Evogene LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
EVGN
Evogene LTD
20-F: Evogene Shifts Focus to AI-Driven Small Molecules Amid Losses
Evogene Ltd. reported a strategic shift to focus on its ChemPass AI platform for small molecule discovery in pharma and agriculture, alongside significant operating losses and a going concern warning for 2025.
NASDAQ
EVGN
Evogene LTD
20-F: Evogene Ltd. Reports Fiscal Year 2024 Results; Outlines Strategic Focus on AI-Driven Drug Discovery
Evogene Ltd. releases its 20-F filing, highlighting financial results for 2024 and a strategic shift towards AI-powered drug discovery.
NASDAQ
EVGN
Evogene LTD
20-F: Evogene Ltd. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023
Evogene Ltd. released its 20-F annual report, detailing its financial performance and operational activities for the fiscal year ended December 31, 2023.